Facebook
Twitter
LinkedIn
Forward
The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion: A Virtual Course (2022)
由泌尿外科协会与泌尿外科肿瘤学会(SUO)合作提出。
除了参加年度/冬季会议和美国大学协会春季会议外，SUO强烈鼓励研究员在研究期间参加至少一门由SUO赞助的教育课程。这门教育课程符合这一建议。
赠送的CME课程!
Monday, September 19 - Tuesday, September 20, 2022 | 4 - 7 p.m. Eastern Time
Join Course Directors, Michael S. Cookson, MD, MMHC, FACS & David F. Jarrard, MD for an educational initiative in advanced prostate cancer.
As a direct result of the significant increase in multiple FDA-approved therapeutic agents for use in patients with advanced prostate cancer, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. This activity will build upon the updated 2020 AUA Guidelines on Metastatic Hormone Sensitive Prostate Cancer (HSPC) and Castration-Resistant Prostate Cancer (CRPC). Topics will include the latest on Genetic Testing in Advanced Prostate Cancer and the Role of Immunotherapy and PARP Inhibitors.
Designed for residents, fellows and APPs as well as urologists and other health care providers who care for patients with prostate cancer, this interactive forum will focus on the application of knowledge with case studies and small group discussion integrated throughout the day. A flipped classroom approach will be utilized. Register early to receive the Prework Library which will be available to all registered participants by August 2022. Participants will be expected to complete the Prework Library in advance of attending the live course - complete the prework on your own time, at your convenience. Then, come prepared on September 19-20 to actively engage with peers as you apply what you've learned.
由于空间有限，请预先登记。
Needs assessment findings show strong support for continued development of courses and educational materials specifically targeted at residents and fellows that cover the medical management of advanced prostate cancer. This activity may also be of interest to urologists and other health care providers who care for patients with prostate cancer.
The Live Forum will cover the following topics*:
- Identification of High Risk Disease and Initial Management of Biochemical Recurrence
- Imaging of Advanced Prostate Cancer
- M0 CRPC: Treatment Options and Goals of Therapy
- Manipulating the Androgen Axis: New Agents in mHSPC and CRPC
- Genetic Testing in Advanced Prostate Cancer
- Bone Health and Radionuclide Therapy
- Role of Immunotherapy and PARP Inhibitors
- Role of Chemotherapy, Treatment Sequencing in mCRPC and Future Directions
*Visit the program tab for full details.
Acknowledgements
This educational activity is supported by independent educational grants from:
- Astellas
- AstraZeneca
- Bayer HealthCare Pharmaceuticals Inc.
- Exact Sciences Corporation
- Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
- Lantheus Medical Imaging
- Pfizer, Inc.
- Sanofi Genzyme
Target Audience
- Urologist
- Resident
- Fellow
- Advanced Practice Provider (Nurse Practitioners & Physician Assistants)
Learning Objectives
At the conclusion of this activity, participants will be able to:
PRACTICE GAP #1 (DISEASE STATE)
- Describe the natural course of advanced prostate cancer from non-metastatic (M0) to metastatic hormone-sensitive disease (mHSPC), with progression to the development of castration-resistant disease (CRPC).
- Describe the treatment options and outcomes for patients with biochemical recurrence after failed local therapy.
- Identify available imaging and indications for use including next generation PET imaging in the assessment of men with biochemical recurrence after failed local therapy.
- Describe the treatment options and outcomes for newly diagnosed mHSPC.
- 解释CRPC对M0和M1管理的影响。
- Discuss the molecular mechanisms and characterization of CRPC.
- Discuss the incorporation of genetic testing (both germline and somatic testing) into the management of men with high risk, metastatic prostate cancer and CRPC.
PRACTICE GAP #2 (GUIDELINES)
- Discuss specific recommendations within the AUA Clinical Practice Guidelines.
- Define M0 CRPC and the treatment options.
- Discuss clinically meaningful endpoints in clinical trials of patients with M0 CRPC.
- Describe gaps in the knowledge for treatment and sequencing of agents in the management of CRPC.
- Discuss challenges in incorporating AUA Guidelines and management of advanced mHSPC and CRPC into community practice.
PRACTICE GAP #3 (ANDROGEN AXIS)
- 确定已批准的用于CRPC治疗的雄激素生物合成和受体阻滞剂。
- Appraise the clinical use and efficacy of approved androgen-axis therapeutics for CRPC.
- 预测、管理和治疗CRPC治疗中针对雄激素轴的治疗干预的不良事件。
- 探讨雄激素轴类药物在M0 CRPC中的新用途。
PRACTICE GAP #4 (CHEMOTHERAPY, IMMUNOTHERAPY, PARP INHIBITORS AND CO-MORBIDITY)
- Identify approved chemotherapeutics, immunotherapy and PARP Inhibitors for mCRPC.
- Describe indications and contraindications for chemotherapy, immunotherapy and PARP Inhibitors in patients with mCRPC.
- 识别共病状态并认识其对mCRPC治疗方案的影响。
- Identify germline and somatic mutations and implications for treatment in mCRPC including indications for PAPR Inhibitors and pembrolizumab.
- Discuss treatment sequencing in the advanced, metastatic and CRPC disease state.
PRACTICE GAP #5 (BONE HEALTH AND RADIONUCLIDE THERAPY)
- Integrate advances in bone health management into patient-specific care plans.
- Identify patients and prescribe radionuclide therapy in appropriate patients with symptomatic mCRPC.
- 讨论已知的与雄激素生物合成抑制剂和放射性核素治疗相关的不良事件。
PRACTICE GAP #6 (PAIN MANAGEMENT AND PALLIATIVE CARE)
- Assess and manage pain in patients with symptomatic mHSPC and mCRPC.
- Discuss the role of chemotherapy, performance status and pain management in patients with mCRPC.
- Review the role of palliative care and supportive services in the management of late stage CRPC.
The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion
Part I – Monday, September 19, 2022
All times are listed inEastern Time
| Agenda | |
|---|---|
| 4:00 — 4:05 p.m. | Welcome Michael S. Cookson, MD, MMHC & David F. Jarrard, MD |
| 4:05 — 4:10 p.m. | Pre-Test Michael S. Cookson, MD, MMHC & David F. Jarrard, MD |
| Session I | |
| 4:10 — 4:30 a.m. | Identification of High-Risk Disease and Initial Management of Biochemical Recurrence Stephen A. Boorjian, MD |
| 4:30 — 4:50 p.m. | Imaging of Advanced Prostate Cancer and Impact on Cancer Management Kelly L. Stratton, MD |
| 4:50 — 5:05 p.m. | M0 CRPC: Treatment Options and Goals of Therapy Michael S. Cookson, MD, MMHC |
| 5:05 — 5:55 p.m. | Case-based Roundtable Discussions: Recurrent and nonmetastatic CRPC
|
| 下午5:55 - 6:15 | Manipulating the Androgen Axis: New Agents in mHSPC and CRPC David F. Jarrard, MD |
| 6:15 — 6:35 p.m. | Genetic Testing in Advanced Prostate Cancer Leonard Gomella, MD, FACS |
| 6:35 — 6:55 p.m. | mHSPC: Maximal Androgen Targeted vs Chemohormonal Therapy for mHSPC and Management of Oligometastatic Disease David F. Jarrard, MD & Joshua M. Lang, MD |
| 6:55 — 7:00 p.m. | Post-Test Michael S. Cookson, MD, MMHC & David F. Jarrard, MD |
Part II – Tuesday, September 20, 2022 |
|
| 4:00 — 4:05 p.m. | Welcome Michael S. Cookson, MD, MMHC & David F. Jarrard, MD |
| 4:05 — 4:10 p.m. | Pre-Test Michael S. Cookson, MD, MMHC & David F. Jarrard, MD |
| Session II | |
| 4:10 — 4:30 p.m. | Bone Health and Radionuclide Therapy Stephen A. Boorjian, MD |
| 4:30 — 4:50 p.m. | Role of Immunotherapy and PARP Inhibitors Alicia Morgans, MD, MPH |
| 4:50 — 5:40 p.m. | Case-based Roundtable Discussions: Chemotherapy-naïve metastatic CRPC
Roundtable Discussants: All Faculty |
| Session III | |
| 5:40 — 6:05 p.m. | Role of Chemotherapy, Treatment Sequencing in mCRPC and Future Directions Joshua M. Lang, MD |
| 下午6:05 - 6:55 | Case-based Roundtable Discussions: Post-Chemotherapy metastatic CRPC
Roundtable Discussants: All Faculty |
| 6:55 — 7:00 p.m. | Post-Test Michael S. Cookson, MD, MMHC & David F. Jarrard, MD |
Education Council Disclosures
COI Review Work Group Disclosures
COI Review Work Group Disclosures
AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.
Michael Cookson, MD,MHA
David Jarrard, MD
Stephen Boorjian, MD
Leonard Gomella, MD
Joshua Lang, MD, MS
Alicia Morgans, MD, MPH
Kelly Stratton, MD
Accreditation:The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation:The American Urological Association designates this live activity for a maximum of 5.75AMA PRA Category 1 CreditsTM．医生只应根据他们参与活动的程度要求相应的荣誉。
Other Learners:AUA没有资格向非MDs或DOs的参与者提供学分。但是，AUA将发布参与文件，声明该活动已获得AMA PRA第1类信用™认证。
Evidence Based Content:It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy:All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Mitigation of Identified Conflict of Interest:All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:
- Peer review for valid, evidence-based content by the AUA COI Review Work Group.
- Attestation that clinical recommendations are evidence-based and free of commercial bias.
- Introduction of a debate format (point-counterpoint)
- Inclusion of moderated panel discussion with unbiased moderator
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Divestiture of the relationship by faculty
- Recusal from controlling relevant aspects of planning
- Selection of alternative faculty for specific topic
Off-label or Unapproved Use of Drugs or Devices:The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Available Credit
- 5.75AMA PRA Category 1 Credit™
- 5.75Non-Physician Participation
Registration for this course iscomplimentary; however should you need to cancel your participation for any reason, please let us know at least two weeks before the course by contactingeducation@auanet.org．
Attendee Information & Policies
AUA Anti-Harassment Policy
AUA Commitment:AUA is committed to providing a safe and productive meeting environment that fosters open dialogue and the exchange of scientific ideas and is free of harassment and discrimination. All meeting participants are expected to behave professionally and treat others with respect, follow venue rules, and alert AUA staff or security of any dangerous situations or anyone in distress.
Reporting Harassment:It is the policy of the AUA that all meeting participants will enjoy an environment free from discrimination, harassment or retaliation. Harassing or offensive behavior by meeting participants will not be tolerated. If an individual experiences or witnesses harassment, he or she should contact Janet Skorepa, AUA EVP, atjskorepa@AUAnet.orgor Diane Bieri, AUA General Counsel, atdbieri@AUAnet.orgor use a venue phone and ask for security if he or she feels unsafe. All complaints will be treated seriously and responded to promptly.
The AUA reserves the right to take any action deemed necessary and appropriate, including refusing or revoking the registration of any individual, without refund, as long as such refusal is consistent with applicable law and AUA policy.
Disclaimer:本项目所包含的教师、作者和其他专家所表达的观点和建议是他们自己的观点，并不一定代表美国泌尿学会(AUA)的观点。世界杯英格兰vs伊朗波胆预测
Consent to Use of Photographic Images:Registration and attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the registrant or attendee's image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities.
Audio, Video, Photographic Equipment:The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.
Reproduction Permission:Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the AUA.
Special Assistance/Dietary Needs:The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, a written request should be submitted at least one month in advance. For additional assistance with your request please call 1-800-908-9414.